{"id":43998,"date":"2022-05-17T15:01:15","date_gmt":"2022-05-17T13:01:15","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/infinity-pharmaceuticals-to-participate-in-upcoming-h-c-wainwright-global-investment-conference\/"},"modified":"2022-05-17T15:01:15","modified_gmt":"2022-05-17T13:01:15","slug":"infinity-pharmaceuticals-to-participate-in-upcoming-h-c-wainwright-global-investment-conference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/infinity-pharmaceuticals-to-participate-in-upcoming-h-c-wainwright-global-investment-conference\/","title":{"rendered":"Infinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment Conference"},"content":{"rendered":"
\n

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Infinity Pharmaceuticals, Inc.<\/a> (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings at the upcoming H.C. Wainwright Global Investment Conference May 23-25, 2022.\n<\/p>\n

<\/a><\/p>\n

\nH.C. Wainwright Global Investment Conference Presentation (hybrid)
\n
Date:<\/b> Tuesday, May 24th<\/sup>, 2022
\n
Time:<\/b> 7:00 am Eastern Standard Time
\n
Speaker:<\/b> Adelene Perkins, Chief Executive Officer
\n
Format:<\/b> Company presentation and virtual 1-on-1 meetings
\n
Webcast Registration Link<\/a>.
\n
\u00a0\u00a0\u00a0\u00a0*a replay will be available following the presentation for 90 days\n<\/p>\n

\nAbout Infinity and Eganelisib
\n
<\/b>Infinity Pharmaceuticals, Inc.<\/a> (\u201cInfinity\u201d or the \u201cCompany\u201d), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic in multiple clinical studies. MARIO-4 is a frontline mTNBC randomized, double-blind, pivotal trial the Company expects to initiate by the end of 2022. MARIO-3 is the first eganelisib combination study in frontline advanced cancer patients and is evaluating eganelisib in combination with Tecentriq\u00ae<\/sup> and Abraxane\u00ae<\/sup> in frontline TNBC and in combination with Tecentriq and Avastin\u00ae<\/sup> in frontline RCC. MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo\u00ae<\/sup> (nivolumab) in I\/O na\u00efve urothelial cancer. MARIO-P is a clinical program to evaluate eganelisib across various solid tumor indications, which the Company expects to initiate on a rolling basis in 3Q 2022. For more information on Infinity, please refer to Infinity’s website at www.infi.com<\/a>.\n<\/p>\n

\nOpdivo\u00ae<\/sup> is a registered trademark of Bristol Myers Squibb.
\n
Tecentriq\u00ae<\/sup> is a registered trademark of Genentech, Inc.
\n
Abraxane\u00ae<\/sup> is a registered trademark of Abraxis BioScience, LLC., a wholly owned subsidiary of Bristol Myers Squibb Company.
\n
Avastin\u00ae<\/sup> is a registered trademark of Genentech, Inc.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nIrina Koffler
\n
LifeSci Advisors, LLC
\n
646-970-4681
\n
ikoffler@lifesciadvisors.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings at the upcoming H.C. Wainwright Global Investment Conference May 23-25, 2022. H.C. Wainwright Global Investment Conference Presentation (hybrid) Date: Tuesday, … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-43998","6":"format-standard","7":"category-industry"},"yoast_head":"\nInfinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment Conference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/infinity-pharmaceuticals-to-participate-in-upcoming-h-c-wainwright-global-investment-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Infinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment Conference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass.–(BUSINESS WIRE)–Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings at the upcoming H.C. Wainwright Global Investment Conference May 23-25, 2022. H.C. Wainwright Global Investment Conference Presentation (hybrid) Date: Tuesday, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/infinity-pharmaceuticals-to-participate-in-upcoming-h-c-wainwright-global-investment-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-17T13:01:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220517005155\/en\/1456663\/21\/INFI_LOGO_TM_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/infinity-pharmaceuticals-to-participate-in-upcoming-h-c-wainwright-global-investment-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/infinity-pharmaceuticals-to-participate-in-upcoming-h-c-wainwright-global-investment-conference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Infinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment Conference\",\"datePublished\":\"2022-05-17T13:01:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/infinity-pharmaceuticals-to-participate-in-upcoming-h-c-wainwright-global-investment-conference\\\/\"},\"wordCount\":301,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/infinity-pharmaceuticals-to-participate-in-upcoming-h-c-wainwright-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220517005155\\\/en\\\/1456663\\\/21\\\/INFI_LOGO_TM_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/infinity-pharmaceuticals-to-participate-in-upcoming-h-c-wainwright-global-investment-conference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/infinity-pharmaceuticals-to-participate-in-upcoming-h-c-wainwright-global-investment-conference\\\/\",\"name\":\"Infinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment Conference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/infinity-pharmaceuticals-to-participate-in-upcoming-h-c-wainwright-global-investment-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/infinity-pharmaceuticals-to-participate-in-upcoming-h-c-wainwright-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220517005155\\\/en\\\/1456663\\\/21\\\/INFI_LOGO_TM_RGB.jpg\",\"datePublished\":\"2022-05-17T13:01:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/infinity-pharmaceuticals-to-participate-in-upcoming-h-c-wainwright-global-investment-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/infinity-pharmaceuticals-to-participate-in-upcoming-h-c-wainwright-global-investment-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/infinity-pharmaceuticals-to-participate-in-upcoming-h-c-wainwright-global-investment-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220517005155\\\/en\\\/1456663\\\/21\\\/INFI_LOGO_TM_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220517005155\\\/en\\\/1456663\\\/21\\\/INFI_LOGO_TM_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/infinity-pharmaceuticals-to-participate-in-upcoming-h-c-wainwright-global-investment-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Infinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Infinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment Conference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/infinity-pharmaceuticals-to-participate-in-upcoming-h-c-wainwright-global-investment-conference\/","og_locale":"en_US","og_type":"article","og_title":"Infinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment Conference - Pharma Trend","og_description":"CAMBRIDGE, Mass.–(BUSINESS WIRE)–Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings at the upcoming H.C. Wainwright Global Investment Conference May 23-25, 2022. H.C. Wainwright Global Investment Conference Presentation (hybrid) Date: Tuesday, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/infinity-pharmaceuticals-to-participate-in-upcoming-h-c-wainwright-global-investment-conference\/","og_site_name":"Pharma Trend","article_published_time":"2022-05-17T13:01:15+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220517005155\/en\/1456663\/21\/INFI_LOGO_TM_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/infinity-pharmaceuticals-to-participate-in-upcoming-h-c-wainwright-global-investment-conference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/infinity-pharmaceuticals-to-participate-in-upcoming-h-c-wainwright-global-investment-conference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Infinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment Conference","datePublished":"2022-05-17T13:01:15+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/infinity-pharmaceuticals-to-participate-in-upcoming-h-c-wainwright-global-investment-conference\/"},"wordCount":301,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/infinity-pharmaceuticals-to-participate-in-upcoming-h-c-wainwright-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220517005155\/en\/1456663\/21\/INFI_LOGO_TM_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/infinity-pharmaceuticals-to-participate-in-upcoming-h-c-wainwright-global-investment-conference\/","url":"https:\/\/pharma-trend.com\/en\/infinity-pharmaceuticals-to-participate-in-upcoming-h-c-wainwright-global-investment-conference\/","name":"Infinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment Conference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/infinity-pharmaceuticals-to-participate-in-upcoming-h-c-wainwright-global-investment-conference\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/infinity-pharmaceuticals-to-participate-in-upcoming-h-c-wainwright-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220517005155\/en\/1456663\/21\/INFI_LOGO_TM_RGB.jpg","datePublished":"2022-05-17T13:01:15+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/infinity-pharmaceuticals-to-participate-in-upcoming-h-c-wainwright-global-investment-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/infinity-pharmaceuticals-to-participate-in-upcoming-h-c-wainwright-global-investment-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/infinity-pharmaceuticals-to-participate-in-upcoming-h-c-wainwright-global-investment-conference\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220517005155\/en\/1456663\/21\/INFI_LOGO_TM_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220517005155\/en\/1456663\/21\/INFI_LOGO_TM_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/infinity-pharmaceuticals-to-participate-in-upcoming-h-c-wainwright-global-investment-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Infinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment Conference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/43998","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=43998"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/43998\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=43998"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=43998"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=43998"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}